BACKGROUND: Hypertonic saline therapy is often used in critically ill subarachnoid hemorrhage (SAH) patients for indications ranging from control of intracranial hypertension to managing symptomatic hyponatremia. The risk factors for developing acute kidney injury (AKI) in this patient population are not well defined. SPECIFIC AIM: To study the role of serum sodium in developing AKI (based on the AKIN definition) in the SAH population admitted to a large academic neurocritical care unit. METHODS: This is an IRB-approved, retrospective cohort study of patients admitted to a tertiary neuro intensive care unit. We included adult (age ≥ 18 years) SAH patients admitted to the neuro intensive care unit for at least 72 h. Development of AKI after admission to the ICU was defined using the AKIN serum creatinine criteria between 72 h and 14 days following admission. A Cox proportional hazards survival model with multiple time varying covariates was developed to evaluate the effect of maximum sodium exposure on the risk of AKI. Sodium exposure was captured as the running maximum of daily maximum serum sodium concentration (mEq/L). Sodium exposure was used as a surrogate for hypertonic saline therapy. RESULTS: The final cohort of patients included 736 patients admitted to the neuro intensive care unit between 2006 and 2012. The number of patients who developed AKI was 64 (9 %). These patients had an increased length of stay (15.6 ± 9.4 vs. 12.5 ± 8.7 days). The odds of death were more than two fold greater among patients who developed AKI (odds ratio 2.33 95 % CI 1.27, 4.3). Sodium exposure was significantly associated with the hazard of developing AKI, adjusting for age, sex, preexisting renal disease, diabetes mellitus, radiocontrast exposure, number of days on mechanical ventilation, and admission Glasgow Coma Scale score. For each 1 mEq/L increase in the running maximum daily serum sodium, the hazard of developing AKI was increased by 5.4 % (95 % CI 1.4, 9.7). CONCLUSION: The maximum daily sodium is a significant risk factor for developing AKI in patients with SAH.
BACKGROUND:Hypertonicsaline therapy is often used in critically ill subarachnoid hemorrhage (SAH) patients for indications ranging from control of intracranial hypertension to managing symptomatic hyponatremia. The risk factors for developing acute kidney injury (AKI) in this patient population are not well defined. SPECIFIC AIM: To study the role of serum sodium in developing AKI (based on the AKIN definition) in the SAH population admitted to a large academic neurocritical care unit. METHODS: This is an IRB-approved, retrospective cohort study of patients admitted to a tertiary neuro intensive care unit. We included adult (age ≥ 18 years) SAHpatients admitted to the neuro intensive care unit for at least 72 h. Development of AKI after admission to the ICU was defined using the AKIN serum creatinine criteria between 72 h and 14 days following admission. A Cox proportional hazards survival model with multiple time varying covariates was developed to evaluate the effect of maximum sodium exposure on the risk of AKI. Sodium exposure was captured as the running maximum of daily maximum serum sodium concentration (mEq/L). Sodium exposure was used as a surrogate for hypertonicsaline therapy. RESULTS: The final cohort of patients included 736 patients admitted to the neuro intensive care unit between 2006 and 2012. The number of patients who developed AKI was 64 (9 %). These patients had an increased length of stay (15.6 ± 9.4 vs. 12.5 ± 8.7 days). The odds of death were more than two fold greater among patients who developed AKI (odds ratio 2.33 95 % CI 1.27, 4.3). Sodium exposure was significantly associated with the hazard of developing AKI, adjusting for age, sex, preexisting renal disease, diabetes mellitus, radiocontrast exposure, number of days on mechanical ventilation, and admission Glasgow Coma Scale score. For each 1 mEq/L increase in the running maximum daily serum sodium, the hazard of developing AKI was increased by 5.4 % (95 % CI 1.4, 9.7). CONCLUSION: The maximum daily sodium is a significant risk factor for developing AKI in patients with SAH.
Authors: Martin W Dünser; Jukka Takala; Hanno Ulmer; Viktoria D Mayr; Günter Luckner; Stefan Jochberger; Fritz Daudel; Philipp Lepper; Walter R Hasibeder; Stephan M Jakob Journal: Intensive Care Med Date: 2009-02-03 Impact factor: 17.440
Authors: Azra Bihorac; Sinan Yavas; Sophie Subbiah; Charles E Hobson; Jesse D Schold; Andrea Gabrielli; A Joseph Layon; Mark S Segal Journal: Ann Surg Date: 2009-05 Impact factor: 12.969
Authors: J Bradley Layton; M Alan Brookhart; Michele Jonsson Funk; Ross J Simpson; Virginia Pate; Til Stürmer; Abhijit V Kshirsagar Journal: Pharmacoepidemiol Drug Saf Date: 2013-08-20 Impact factor: 2.890
Authors: David A Zygun; Christopher J Doig; Arun K Gupta; Gemma Whiting; Claryn Nicholas; Edna Shepherd; Christine Conway-Smith; David K Menon Journal: J Crit Care Date: 2003-12 Impact factor: 3.425
Authors: Andrew J Molyneux; Richard S C Kerr; Ly-Mee Yu; Mike Clarke; Mary Sneade; Julia A Yarnold; Peter Sandercock Journal: Lancet Date: 2005 Sep 3-9 Impact factor: 79.321
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Tibor Fülöp; Lajos Zsom; Rafael D Rodríguez; Jorge O Chabrier-Rosello; Mehrdad Hamrahian; Christian A Koch Journal: Rev Endocr Metab Disord Date: 2019-03 Impact factor: 6.514
Authors: Abby M Basalely; Russell Griffin; Katja M Gist; Ronnie Guillet; David J Askenazi; Jennifer R Charlton; David T Selewski; Mamta Fuloria; Frederick J Kaskel; Kimberly J Reidy Journal: J Perinatol Date: 2021-11-13 Impact factor: 3.225